Loading...
Market
First significant HACE breakthrough field by end of 2025?
2
Resolution / Starting Odds
Cancer Research • 25%
Genetic Disorders • 25%
Neuroscience • 25%
Other • 25%
Scientific publications and news reports on breakthroughs
Story
New CRISPR Tool HACE Enables Long-Range Targeted Mutagenesis in Mammalian Genomes Published in Science Magazine
Oct 11, 2024, 02:30 PM
A new CRISPR-based tool called Helicase-Assisted Continuous Editing (HACE) has been developed for long-range, targeted mutagenesis of over 1000 base pairs in mammalian genomes. This tool allows researchers to explore the effects of genetic variants on gene function and regulation in both coding and non-coding regions. The research, co-authored by Brad E. Bernstein from Dana-Farber Cancer Institute and published in Science Magazine, expands the functional genomics toolbox. It demonstrates that HACE can continuously generate mutations over a 10-day period and enables targeting using dCas9 without introducing DNA nicks.
View original story
Similar markets
Particle Physics • 25%
Medical Imaging • 25%
Quantum Computing • 25%
Other • 25%
Phase 1 completion • 25%
Phase 2 completion • 25%
Phase 3 completion • 25%
No significant milestone • 25%
Protein Structure Elucidation • 25%
Drug Discovery • 25%
Genomic Research • 25%
Other • 25%
Drug Discovery • 25%
Genetic Research • 25%
Agricultural Improvement • 25%
Other • 25%
Alzheimer's Disease • 25%
Parkinson's Disease • 25%
Schizophrenia • 25%
Other • 25%
Drug Discovery • 25%
Agricultural Biotechnology • 25%
Personalized Medicine • 25%
Other • 25%
Supernova • 25%
New planetary bodies • 25%
Unique chemical composition • 25%
Other • 25%
China • 25%
United States • 25%
Germany • 25%
Other • 25%
AI Training Speed • 25%
Robotics Efficiency • 25%
4D Simulation Quality • 25%
Other • 25%
Cancer treatment development • 25%
Antibiotic resistance solutions • 25%
Neurodegenerative disease therapy • 25%
Other • 25%
Enhanced drone technology • 25%
AI software for military • 25%
Cyber defense systems • 25%
Other • 25%